TYRA (Tyra Biosciences Inc) רווח למניה בארבעת הרבעונים האחרונים

After assessing the current EPS YoY TTM growth rate on GURU.Markets, we find that -40.50 captures the value of this parameter for Tyra Biosciences, Inc. (TYRA). Growth is hindered by strict FDA oversight and the patent protection of the SNAP platform. Meanwhile, the company attracts leading oncologists through flexible working conditions. The business is fully insulated from global political tensions and logistical disruptions, maintaining a neutral backdrop.
Tyra Biosciences Inc - פילוחים אנליטיים ומדדי מפתח (TYRA)

This indicator assesses the dynamics of net income per share over a rolling year, eliminating the volatility of one-time payments by comparing the current TTM period with the corresponding prior period. By analyzing the YoY EPS growth rate over the last 12 months, an investor can gauge the capital management efficiency of Tyra Biosciences, Inc. (TYRA), where in the absence of revenue, the metric reflects only the cash burn rate for R&D.